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1. Introduction
Diabetes occurs in 366 million people worldwide and is pro-
jected to affect 552 million people by 2030 [1]. In the United States 
alone, an estimated 25.8 million people have this disease [2]. Di-
abetes can be described as a group of disorders that result from 
insulin deficiency and/or insulin resistance. Insulin is a hormone 
produced in the pancreas and is responsible for the regulation of 
glucose in the circulation [3]. The presence of either insulin defi-
ciency or insulin resistance in diabetes produces an abnormal in-
crease in blood glucose, resulting in a condition known as hyper-
glycemia. The high blood glucose concentrations seen in diabetes 
can lead to a number of detrimental health effects, ranging from 
an increased risk of heart disease and stroke to kidney disease, 
blindness, and lower limb amputations [4–8].
Two of the most prevalent forms of this disease are types 1 
and 2 diabetes [1]. In type 1 diabetes, insufficient production of 
insulin is caused by an autoimmune response in which the body’s 
immune system attacks insulin-producing pancreatic beta cells 
[1, 2]. Type 1 diabetes is also known as juvenile-onset, immune-
mediated or insulin-dependent diabetes. Patients with this type 
of diabetes require daily insulin injections for survival. Type 1 
diabetes accounts for approximately 5–10% of individuals who 
have diabetes. Type 2 diabetes is also known as non-insulin de-
pendent or adult-onset diabetes; this is the most common form 
of diabetes and accounts for 90–95% of individuals with this 
disease. Type 2 diabetes is caused by an inadequate cellular re-
sponse to insulin (i.e., by muscle, liver, or adipose cells), or “in-
sulin resistance”, and is strongly associated with factors that in-
clude obesity, age, and family history [1, 2].
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Abstract
Glycation involves the non-enzymatic addition of reducing sugars and/or their reactive degradation products to amine 
groups on proteins. This process is promoted by the presence of elevated blood glucose concentrations in diabetes and oc-
curs with various proteins that include human serum albumin (HSA). This review examines work that has been conducted 
in the study and analysis of glycated HSA. The general structure and properties of HSA are discussed, along with the re-
actions that can lead to modification of this protein during glycation. The use of glycated HSA as a short-to-intermediate 
term marker for glycemic control in diabetes is examined, and approaches that have been utilized for measuring glycated 
HSA are summarized. Structural studies of glycated HSA are reviewed, as acquired for both in vivo and in vitro glycated 
HSA, along with data that have been obtained on the rate and thermodynamics of HSA glycation. In addition, this review 
considers various studies that have investigated the effects of glycation on the binding of HSA with drugs, fatty acids and 
other solutes and the potential clinical significance of these effects.
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Many of the long-term effects of diabetes can be related to the 
process of protein glycation. Glycation involves the non-enzymatic 
addition of reducing sugars and/or their reactive degradation prod-
ucts to primary or secondary amine groups on proteins [9, 10]. Early 
stage glycation involves the nucleophilic attack of a reducing sugar 
with primary amine groups on proteins to form a Schiff base, as 
shown in Figure 1(a). This intermediate product can then undergo 
a slow rearrangement to create a more stable Amadori product, or 
ketoamine (i.e., fructosyl–lysine, or FL, when this reaction involves 
glucose) [11–15]. Further oxidation, dehydration, and cross-linking 
steps can then occur, such as through the formation of reactive di-
carbonyl compounds. These latter compounds exhibit significantly 
enhanced reactivity for sites such as arginine and lysine residues on 
proteins, as illustrated in Figure 1(b), with the result being the cre-
ation of advanced glycation end-products (AGEs) [12].
The study of proteins containing either early stage glycation 
products or AGEs has become of great interest due to the suspected 
effects of glycation on protein function and tissue damage during 
diabetes. This effect has been well-studied for proteins with long life 
spans, such as collagen and lens crystallin [16, 17], as well for some 
proteins with shorter life spans, such as hemoglobin [18]. However, 
there has also been an increasing interest in the glycation of human 
serum albumin (HSA) and closely-related proteins (e.g., bovine se-
rum albumin, or BSA). This interest is illustrated in Figure 2 by the 
increasing number of publications that have appeared on this topic 
over the last few decades, and especially over the last ten years.
This review will discuss past and recent reports that have ex-
amined the glycation of albumins, and especially HSA. This will 
include a discussion of the structure and function of HSA, the pro-
cess of glycation, and the measurement of glycated HSA for clin-
ical purposes. The types of structural modifications that can ap-
pear as a result of glycation on albumin and the analysis of these 
modifications will also be considered. The rate and thermodynam-
ics of glycation for HSA will be examined. In addition, the bind-
ing of drugs and solutes to glycated HSA and the possible clinical 
significance of glycation-related modifications on the function and 
behavior of HSA will be discussed.
2. Structure and function of human serum albumin
HSA is the most abundant protein in human plasma or serum. 
This protein is normally present in serum at concentrations rang-
ing from 30 to 50 g/L and accounts for approximately 60% of the 
total protein content in serum [19, 20]. HSA has a molecular weight 
of 66.7 kDa and is composed of a single polypeptide chain with 585 
amino acids and 17 disulfide chains. The crystal structure of HSA 
reveals a globular heart-shaped protein composed of approximately 
67% α-helices, 23% extended chains, and 10% β-turns (see Figure 3) 
[19, 21–25]. The N-terminus and 59 lysine residues can act as poten-
tial sites for the formation of early stage glycation products on this 
protein, as illustrated by the reaction in Figure 1, although not all of 
these groups are equally susceptible to this reaction  [19, 26]. HSA 
also has 24 arginines that, along with the lysines and N-terminus, 
could potentially be involved in the formation of AGEs [19].
Figure 1. The process of glycation, which begins during early stage glycation (a) with the reaction of a reducing sugar such as d-glucose with a free 
amine group on a protein to form a reversible Schiff base, followed by the formation of a more stable Amadori product (i.e., fructosyl–lysine, or 
FL, in the case of glucose). The open chain glucose adducts can also convert to the closed forms that are shown above, which represent an N-sub-
stituted aldosylamine in the case of the Schiff base or an N-substituted 1-amino-1-deoxyketose in the case of the Amadori product [15]. These early 
stage glycation reactions can later be followed by additional events during advanced stage glycation (b) that lead to the formation of advanced gly-
cation end-products (AGEs). More details on the structures of FL and common AGEs are provided in Figure 6.
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HSA is involved in many physiological processes. For instance, 
this protein aids in the regulation of osmotic pressure and pH in 
blood. In addition, HSA mediates lipid metabolism, sequesters 
toxins, and works as an antioxidant (i.e., it binds free radicals) [19]. 
Another important function of HSA is its action as a transport pro-
tein for a wide range of solutes that include some low mass hor-
Figure 3. The crystal structure of 
HSA. The locations of the main drug 
binding sites in this protein (i.e., Sud-
low sites I and II) are shown, as well 
as the locations for several lysines 
that have often been reported to take 
part in glycation. This structure was 
generated using Protein Data Bank 
(PDB) file ID: 1AO6.
Figure 2. Number 
of publications that 
have appeared over 
the last three decades 
that are related to the 
topic of glycation in-
volving albumin or 
human serum albu-
min (HSA). These 
numbers were ob-
tained on SciFinder 
in February 2013 us-
ing the key terms 
“glycated” or “glyco-
sylated” and “albu-
min” or “HSA”.
R e v i e w :  G l y c a t i o n  o f  h u m a n  s e R u m  a l b u m i n   67
mones, fatty acids, and drugs [19, 24, 27–32]. There are several bind-
ing sites located in the structure of this protein. For example, 
crystallographic studies have shown that HSA has various binding 
sites for fatty acids [27, 30]. This protein also has two major binding 
sites for drugs (i.e., Sudlow sites I and II, as shown in Figure 3), in 
addition to several minor sites for small solutes [19, 24, 31–34]. Sud-
low site I is located in sub-domain IIA of HSA and is also known as 
the warfarin–azapropazone binding site. This region tends to bind 
to bulky heterocyclic compounds, such as warfarin, azapropazone, 
and phenylbutazone [19, 24, 31, 35]. Sudlow site II is located in sub-
domain IIIA of HSA and is also referred to as the indole–benzo-
diazepine binding site. This site is the primary binding region on 
HSA for aromatic compounds such as ibuprofen and indole-con-
taining compounds (e.g., l-tryptophan) [19, 24, 31, 36].
3. Measurement of glycated albumin
The measurement of glycated HSA (or “glycated albumin”, 
GA, as it is often called in the clinical literature) has been of inter-
est for a number of years as a complementary tool to standard as-
says using glucose or glycated hemoglobin (i.e., hemoglobin A1c, 
or HbA1c) to monitor glycemic control in diabetic patients. Blood 
glucose is a standard test for the diagnosis and monitoring of di-
abetes, but only provides information on the glycemic status of a 
patient at a particular moment in time [37]. HbA1c is an accepted 
biomarker for providing a long-term record of glycemic control 
over a period of 2–3 months, as made possible by the life span of 
approximately 90–120 days for hemoglobin in red blood cells [38, 
39]. However, it has been suggested that HbA1c may not be suit-
able for evaluating patients with unstable blood glucose concen-
trations, and the accuracy of this marker can be affected by the 
presence of hemoglobin variants [40], recent blood transfusions or 
diseases such as hemolytic anemia and renal failure, which can af-
fect the production and effective life span of red blood cells in the 
circulation [41, 42].
These limitations in current methods have generated interest 
in other markers and tests for the assessment of glucose control, 
especially for examining the control of blood glucose over short-
to-intermediate lengths of time [38]. The utilization of glycated 
HSA for this purpose has been suggested because the half-life of 
HSA in the blood is only 12–21 days [37–39]. This means that as-
says for glycated HSA, or related markers, can provide informa-
tion on glucose control over a period of roughly of 2–3 weeks. This 
feature, in turn, could help physicians to detect deteriorating con-
trol of blood glucose before any noticeable changes in HbA1c oc-
cur [37, 43, 44].
Fructosamine assays have been explored by clinical labora-
tories as means for measuring glycation that is mainly related to 
HSA [37, 38, 45]. The term “fructosamine” (often abbreviated as 
“FA”) typically refers to all ketoamine linkages that result from the 
glycation of serum proteins. Because HSA is the most abundant of 
the serum proteins, fructosamine is predominantly a measure of 
glycated HSA, contributing ~ 90% to the total [41, 42]. As a result, 
fructosamine assays tend to be used when glycemic control needs 
to be examined over a period of 1–3 weeks [37, 38, 42]. Colorimet-
ric methods such as the thiobarbituric acid (TBA), nitroblue tet-
razolium (NBT) and hydrazine-based assays have been employed 
to measure glycated serum proteins [45–47]. For example, the NBT 
assay relies on the ability of N-substituted ketoamines to reduce 
the dye nitroblue tetrazolium in a basic solution, generating a col-
ored product [45, 48]. Although fructosamine assays are popular in 
some countries, they have not seen as much use in the U.S., partly 
due to difficulties encountered in the commercialization of such 
methods [38]. Further details on the performance characteristics of 
these techniques are provided in Refs. [38, 42–47].
The concentration of glycated HSA can be measured directly 
by a number of techniques. These methods include boronate affin-
ity chromatography [38, 49–55], immunoassay-related techniques 
(e.g., enzyme-linked immunosorbent assays or radio-immunoas-
says) [38, 56, 57] and enzymatic methods [58–61]. Profiling of gly-
cated proteins in human serum, including HSA, has also been 
explored using boronate affinity chromatography followed by tan-
dem mass spectrometric detection [62]. The boronate affinity chro-
matographic methods make use of the interaction between sugar 
residues and a binding agent such as phenylboronic acid; this pro-
cess allows for the retention and separation of glycated HSA from 
non-glycated HSA (see Figure 4), with the retained species later 
being detected and quantified by an on-line or off-line method 
(e.g., mass spectrometry or an immunoassay) [38, 49–53, 55]. Bor-
onates have also been used in an enzyme-linked boronate immu-
noassay to measure glycated HSA [57]. One current clinical assay 
based on an enzymatic method utilizes an albumin-specific pro-
teinase (i.e., ketoamine oxidase) to digest glycated HSA, followed 
by treatment with a fructosaminase to oxidize the glycated amino 
acids and produce hydrogen peroxide, which is then measured 
[59–61]. Raman spectroscopy [63], refractive index measurements 
[64], capillary electrophoresis [65] and other electrophoretic meth-
ods [66, 67] have also been explored as alternative techniques for 
measuring glycated albumin.
The clinical assays for glycated HSA typically express their re-
sults in terms of the ratio of the amount of glycated HSA versus 
the total amount of HSA that is present. This feature means that 
these methods are not generally affected by changes in the overall 
concentration of HSA [38, 41]. Prior work from the 1980s estimated 
that 6–13% of HSA was glycated in healthy individuals, with this 
amount increasing by up to 20–30% in diabetic patients [26, 38, 68, 
69, 70]. A recent review noted that a normal reference range of 11–
16% is used with a commercial enzymatic-based method, and cur-
rent assays based on affinity chromatography often have lower ref-
erence values in the range of 0.6–3% [38]. However, all current 
methods tend to give typical glycated HSA values for diabetic pa-
tients that are 2- to 5-fold higher than normal levels [38]. Altered 
albumin metabolism can affect glycated HSA measurements in pa-
tients that suffer from proteinuria, hepatic cirrhosis or hypothy-
roidism [41]. In addition, elevated amounts of glycated HSA have 
been noted to occur with several vascular complications and to be 
linked to immune function, oxidative stress, cholesterol homeo-
stasis, and atherosclerosis [39].
4. Structural analysis of glycated albumin
The process of glycation has been found to have possible ef-
fects on both the structure and function of HSA [26, 71]. For in-
stance, several reports have found altered drug binding with this 
protein as a result of glycation [71–75], as will be discussed in Sec-
tion 6. The study of alterations in the structure of HSA following 
glycation has involved the use of radio-labeling [76–78], colori-
metric assays [48], fluorescence spectroscopy [26, 79–82], infrared 
spectroscopy [79], circular dichroism [71, 82, 83], and NMR spec-
troscopy [84]. In addition, work based on immunoassays [79–85], 
electrophoresis [81, 86] and HPLC [78, 81, 87–89] has provided in-
formation on the total glycation levels or on the amount of spe-
cific AGEs that are present within albumin. Some of these ap-
proaches again include the prior isolation of modified albumin 
by methods such as boronate affinity chromatography [38, 49–55, 
76, 78, 79, 90–92].
More detailed information on glycated-related modifications 
has been obtained by using mass spectrometry. For instance, liq-
uid chromatography–mass spectrometry (LC–MS) and liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) have 
been used to locate and identify glycation sites in albumin [92–97], 
to identify glycated peptides obtained from serum proteins [91], 
and to look at the sites involved in the related process of galacta-
tion (i.e., the addition of galactose to an amine group) [98] and in 
the formation of some AGEs [99, 100]. High resolution mass spec-
trometry (HRMS) [101] and tandem mass spectrometry (MS/MS) 
[101, 102] have also been used to detect glycated peptides or to iden-
tify glycation sites. Fourier transform mass spectrometry (FTMS) 
has been utilized to detect and identify glycated peptides from 
HSA [103]. Gas chromatography–mass spectrometry (GC–MS) 
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has been employed to investigate glycation at the N-terminus of 
HSA [104]. In addition, matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI–TOF MS) has been 
used to estimate the overall extent of modification for glycated 
HSA, to study glycated BSA, to locate sites for early stage glycation 
products in HSA, to identify various AGEs in HSA, and to compare 
the extent of modification at various regions of glycated HSA [80, 
92, 102, 105–111].
The process of glycation can be divided into several stages [10–
12]. The first stage of this process, as shown earlier in Figure 1(a), 
involves the combination of a reducing sugar such as glucose with 
primary amine groups (e.g., lysine residues or the N-terminus of 
a protein) to form a reversible Schiff base; this product can then 
slowly rearrange to form an Amadori product [10–14]. Fructosyl–
lysine (FL, see Figure 1) is the major Amadori product produced in 
vivo and has been found to occur at various locations in glycated 
HSA. Table 1 summarizes the results of numerous studies that 
have examined the glycation process and the creation of Amadori 
products for both in vitro and in vivo glycated HSA [76, 78, 80, 93–
95, 97, 101, 105–108, 110].
The combined list of modification sites that have been reported 
for FL and Amadori products includes all 59 lysines in HSA (see 
Figure 5). However, only a relatively small number of these res-
idues appear to account for most of the Amadori products and 
modifications that are found in glycated HSA. As Figure 5 illus-
trates, lysine 525 has consistently been found to be a major site 
for the formation of such products within both in vivo and in vitro 
glycated HSA [76, 78, 108]. Other glycation sites that have been ob-
served in at least half of the reported studies in Table 1 include ly-
sines 439, 199, 51, 378, 545, 12, 233, 276, 281, 317 and 323. It is in-
teresting to note that lysine 525 and many of these same lysines 
have been reported to be important sites for the addition of ga-
lactose to HSA in vitro [98]. An additional 23 lysine residues have 
been found to be modified for glycated HSA in at least four of the 
reports listed in Table 1. Besides these lysine residues, the N-ter-
minus has been noted in some reports to be a site for glycation in 
HSA [80, 104, 106, 108]. Factors involved in determining the relative 
susceptibility of these lysines and the N-terminus to glycation in-
clude local acid–base catalysis effects, the accessibility of the site 
to the solvent or the environment, and the local pKa for the amine 
group at each site [78, 96, 106, 108, 110].
The next stage of the glycation process involves the oxidation 
of adducts on glycated proteins or free sugars to form intermediate 
reactive dicarbonyl compounds, or α-oxaloaldehydes [28, 88, 112–
118]. The α-oxaloaldehydes that have been most commonly corre-
lated with diabetes, kidney disease, and cardiovascular disease in 
vivo are glyoxal, methylglyoxal, and 3-deoxyglycosone [89, 115]. The 
concentrations of these α-oxaloaldehydes typically increase from 
sub-nanomolar concentrations in normal individuals to micromo-
lar concentrations in a number of diseases [116]. α-Oxaloaldehydes 
can react with both lysines and arginines to form AGEs, as illus-
trated in Figure 1(b), and can also lead to the modification of cys-
teine residues [81]. AGE formation on plasma proteins is mediated 
by a number of competing processes that include the oxidation of 
sugars, lipids, or protein-bound sugar adducts and the counteract-
ing removal of reactive dicarbonyl compounds by the glyoxylase 
pathway or through natural protein degradation [116].
Table 1 includes a list of AGEs that have been observed in stud-
ies of both in vitro and in vivo glycated HSA [80, 96, 97, 105–108, 110]. 
Examples of these AGEs are shown in Figure 6. As indicated in 
Table 1, methylglyoxal-derived hydroimidazolone isomer 1 (MG-
H1) and glyoxal-derived hydroimidazolone isomer 1 (G-H1) have 
been seen in several studies for in vitro or in vivo glycated HSA. 
The corresponding hydroimidazolone derived from 3-deoxyglu-
cosone (3-DG-H1, isomer 1) has also been observed in these sam-
ples. Other possible AGEs that have been reported for both in vivo 
and in vitro samples of glycated HSA include additional products 
related to arginine, such as tetrahydropyrimidine (THP); prod-
ucts related to lysines, such as Nε-carboxyethyl–lysine (CEL), Nε-
carboxymethyl–lysine (CML) and pyrraline (Pyr); and products 
related to either lysines or arginines, such as 1-alkyl-2-formyl-3,4-
glycosyl-pyrrole (AFGP). In addition, the arginine-related prod-
ucts argpyrimidine (ArgP) and imidazolone B (IB) have been ob-
served for glycated HSA in vitro [99, 100, 106, 107].
Some studies have compared the relative amounts of these 
AGEs that can be found in HSA and the residues that may take 
part in these modifications. For instance, minimally glycated 
HSA that was prepared in vitro was found to contain mainly FL 
Figure 4. Use of a col-
umn and support contain-
ing a boronate ligand (e.g., 
phenylboronic acid) for the 
retention of glycated HSA. 
The active binding agent 
in this process is the tet-
rahedral boronate anion, 
which forms under alka-
line conditions.
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Modification 
process [Ref.]
Glycation [76]
Glycation [78]
Glycation [94]
Glycation [95]
Glycation [93]
Glycation [101]
Glycation [97]
Glycation and AGE 
formation [96]
Glycation and AGE 
formation [80]
Glycation and AGE 
formation [107]
Glycation and AGE 
formation [106]
Glycation and AGE 
formation [105]
Glycation and AGE 
formation [108]
Glycation and AGE 
formation [110]
AGE formation with 
methylglyoxal [99, 
100]
Galactation [98]
Sample (glycation conditions)b  
and analysis methods
In vivo sample; tritium labeling, boronate 
affinity chromatography, cation exchange 
chromatography and amino acid analysis
In vivo sample; tritium labeling, boronate 
affinity chromatography, HPLC and amino 
acid analysis
In vitro sample (330-fold mol excess glucose 
vs. 1.5 mM HSA, 37 °C, 28 days); LC–MS/MS
In vivo sample; LC–MS
In vivo samples; boronate affinity 
chromatography and LC–MS/MS
In vitro sample (370-fold mol excess glucose 
vs. lyophilized HSA, 80 °C, 25 min); 
13C-labeling, HPLC, HRMS and MS/MS
Plasma sample incubated with 30 mM glucose 
(37 °C, 24 h); 12C/13C-labeling, boronate 
affinity chromatography, LC–MS/MS
In vitro sample (330-fold mol excess glucose 
vs. 1.5 mM HSA, 37 °C, 28 days); LC–MS/MS, 
MALDI–TOF MS
In vitro sample (3125-fold mol excess glucose 
vs. 16 μM HSA, 40 °C, up to 115 days); 
MALDI–TOF MS
In vitro sample (commercial preparation 
of minimally-glycated HSA); peptide 
fractionation, MALDI–TOF MS
In vitro samples (24- to 48-fold mol excess 
glucose vs. 0.63 mM HSA, 37 °C, 2–5 weeks); 
peptide fractionation, MALDI–TOF MS
In vitro sample (commercial preparation of 
minimally-glycated HSA); 16O/18O-labeling, 
peptide fractionation, MALDI–TOF MS
In vitro samples (24-fold mol excess glucose vs. 
0.63 mM HSA, 37 °C, 2–5 weeks); 16O/18O-
labeling, peptide fractionation, MALDI–TOF 
MS
In vivo sample; 16O/18O-labeling, peptide 
fractionation, MALDI–TOF MS
In vitro samples (5-fold mol excess of glucose 
vs. 0.1 mM HSA at 37 °C, 24 h); LC–MS/MS
In vitro samples (8- to 1500-fold mol excess 
galactose vs. 1.2 μM HSA, 37–56 °C, 0.01–
8 days); boronate affinity chromatography, 
LC–MS/MS
Modification sites identified 
Major site: K525
Major site: K525; other significant sites: K199, K233, K281, 
K439; additional sites identified: K12, K317, K351, K534
K12, K20, K41, K51, K73, K136, K137, K159, K162, K199, K205, 
K233, K262, K276, K281, K313, K317, K323, K351, K378, 
K389, K402, K432, K436, K439, K475, K500, K519, K525, 
K541, K545, K557, K574
K525 > K233 > K136/K137 > K199, K64/K73, K439, K317, 
K274/K276 > K534 > K389c
K524/K525 > K162 > K276 > K359 > K351 > K233; additional 
sites identified: K12, K51, K64, K174, K181, K262, K378, 
K414, K475, K541, K545d
K4, K41, K73, K137, K181, K190/K195, K199/K205, K225/
K233, K323,e K351, K378, K413/K414, K432, K436/K439, 
K466, K519, K524/K525, K536, K545, K564/K573
Preferential sites: K525, K240, K233, K51, K136, K137, K73; 
other sites: K41, K64, K93, K106, K159, K174, K181, K195, 
R218, K262, K274, K323, K359, K372, K378, K389, K402, 
K413, K432, K436, K439, K444, K466, R472, K475, K500, 
K519, K573d
K51, K137, K162, K225, K233, K276, K313, K323, K351, K378, 
K413, K444, K525, K536, K545, K573
Potential sites: K41, K64, K93, K106, K317, K323, K359, K372, 
K402, K439, K444, K525, K541, K545, K557, K560, K564, 
K573, K574, R10, R98; Other potential sites: K4, K51, K281, 
K286, K313, R160, R209
K12, K51, K159, K199, K205, K286, K378, K439, K525, K538; 
R160, R222, R472
Significant sites: K525/K524/R521 > N-Terminus, K93/R98, 
K276/K286, K414/K439 > R197 > K199, K281, R428; Other 
sites: K4, K12, K174, K190, K205, K212, K262, K313, K317, 
K413, K545, K557, K560, K564, K573, K574; R10, R186, 
R209, R410
K159, K212, K323, K413, K432, K439, K525; R81, R114, R218
Regions with highest levels of modification (likely sites): 1–10 
(N-terminus*/K4/R10) or 42–51 (K51), 521–531 (K525*/
K524), 275–286 (K281*/K276/K286), 21–41 (K41), 82–93 
(K93), 87–100 (K93/R98), 101–119 (K106/R114/R117), 146–
160 (K159/R160), 360–372 (K372); other regions: 426–442 
(K439*/R428), 61–82 (K64/K73/R81), 142–153 (R144/
R145), 154–167 (K159), 189–208 (K199), 209–227 (K212/
R218), 241–257 (R257), 324–336 (R336), 373–389 (K378/
K389), 414–428 (K414/R428), 502–518 (K519) f
K12, K162, K174, K190, K199, K205, K276, K281, K286, K313, 
K317, K372, K432, K525, K545, K557, K560, K564, K573/
K574; R10, R98, R160, R197, R209, R428, R484, R485
R410 > R114, R186, R218, R428
K12, K233, K276/K281, K414, K525
Major adducts 
FL/Amadori products
FL/Amadori products
FL/Amadori products
FL/Amadori products
FL/Amadori products
FL/Amadori products
FL/Amadori productsand 
AGEs
FL/Amadori products and 
AGEs
FL/Amadori products and 
AGEs
FL/Amadori products and 
AGEs (e.g., AFGP, ArgP, 
CEL, CML, 3DH-H1, 
G-H1, Pyr, THP)
FL/Amadori products and 
AGEs (e.g., AFGP, ArgP, 
CEL, CML, 3-DG-H1, 
G-H1, IB, MG-H1, Pyr, 
THP)
FL/Amadori products and 
AGEs (e.g., AFGP, CEL, 
CML, Pyr)
FL/Amadori products and 
AGEs (e.g., AFGP, CEL, 
3-DG-H1, G-H1, Pyr, 
MG-H1)
FL/Amadori products and 
AGEs (e.g., AFGP, CEL, 
CML, 3-DG-H1, G-H1, 
MG-H1, Pyr, THP)
MG-H1, ArgP, CEL, 
methylglyoxal-derived 
lysine dimer
Galactosyl–lysine
Table 1. Modification sites and adducts that have been reported for glycated human serum albumin (HSA).a
a. A ranking of the modified residues is provided if such information appeared in the given references. If no ranking was provided, then the modification sites are listed 
in their order of appearance in HSA. List of abbreviations: AFGP, 1-alkyl-2-formyl-3,4-glycosyl-pyrrole; AGE, advanced glycation end-product; ArgP, argpyrimidine; 
CEL, Nε-carboxyethyl–lysine; CML, Nε-carboxmethyl–lysine; 3-DG-H1, 3-deoxyglucosone-derived hydroimidazolone, isomer 1; FL, fructosyl–lysine; G-H1, glyoxal-
derived hydroimidazolone, isomer 1; IB, imidazolone B; MG-H1, methylglyoxal-derived hydroimidazolone, isomer 1; Pyr, pyrraline; THP, tetrahydropyrimidine.
b. A typical ratio of glucose to HSA that is found in blood during diabetes is 24:1 (mol/mol) and the normal concentration of HSA in serum is generally 0.53–0.75 mM 
(i.e., 35–50 g/L).
c. The order of these results are those for the “Diabetic patient” in Table 1 of Reference [95]. A similar order was obtained for other samples that were examined.
d. The values differ from the published residues by 24 amino acids to exclude the signaling peptide that was included in the sequence in this study and to make the listed 
sequence assignments consistent with the rest of the table.
e. This paper included an entry for K322 which should have instead been K323, according to a personal communication with the authors.
f. This study focused on quantitative studies based on the examination of a decrease in the abundance of non-modified peptides from the indicated regions. The 
suspected modification sites leading to each decrease are those contained in the given regions, as based on the sequence of HSA, identified modifications, and prior 
studies of glycated HSA; in cases where a particular residue is a well-known modification site from prior work, this residue is indicated by an asterisk. This list 
combines the modified regions that were seen for two in vitro samples that were incubated either two or five weeks with the stated amount of glucose. For 502–518, 
which contains no lysine or arginine, K519 is given as a possible site of modification because it is immediately next to the enzymatic digestion site for this peptide.
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and CML plus minor amounts of others AGEs (e.g., ArgP, 3DG-
H1, G-H1, MG-H1, THP and some 3-deoxyglucosone-derived ly-
sine dimer); in vitro highly glycated HSA that was examined by the 
same methods contained the same AGEs plus pyrraline and high 
amounts of FL [88, 89]. Quantitative screening for several types of 
AGEs in plasma proteins, including HSA, indicated that hydro-
imidazolones were a major type of modification that occurred in 
this group. Of these, MG-H1 was estimated to be present in about 
2% of HSA from normal healthy individuals, followed by 1% for 
3DG-H (e.g., 3DG-H1) and 0.1% for G-H1 [117]. AGEs such as CML, 
CEL were found in the same types of samples at amounts just be-
low those of G-H1, while only small amounts of cross-linked spe-
cies like pentosidine and methylglyoxal-derived lysine dimer were 
detected. The levels of these modifications were found, in general, 
to increase in patients with renal failure [117].
It has been noted that the reaction of methylglyoxal with 
0.11 mM HSA at pH 7.4 and 37 °C tends to be selective for arginine 
residues at a methylglyoxal concentration of 1 mM, with a much 
higher methyglyoxal concentration (100 mM) leading to increased 
modification for arginines as well as the modification of some ly-
sines [81]. Of the 24 arginines that are present in HSA, 21 of these 
have already been proposed to take part in some type of AGE for-
mation, as is illustrated in Figure 5. This observation agrees qual-
itatively with in vitro studies of HSA from Ref. [81], in which the 
incubation of this protein with over a 900-fold mol excess of 
methylglyoxal resulted in the modification of an average of 19 out 
of 24 arginines per HSA. The arginines which have been found 
to be modified in four or more studies of AGEs for in vitro or in 
vivo glycated HSA are R128, R428, R10, R98, R114, and R160; 
another four arginines have been noted to be modified in at least 
three studies of glycated HSA. Studies that have examined the in 
vitro reaction of methylglyoxal with HSA have found that R410 is a 
particularly active site for this pair of reactants, followed by R114, 
R186, R218 and R428 [99, 100].
The use of glycated HSA as a biomarker for glycemic control, as 
discussed in Section 3, is based on the fact that the extent of glyca-
tion for this protein will depend on the time allowed for glycation 
and the amount of glucose that is available for reaction with HSA. 
As will be shown in Section 5, the types of modifications that occur 
on glycated HSA will also depend on these factors. Furthermore, 
this means some variations in glycation-related modifications may 
occur between samples of in vitro glycated HSA that are prepared 
under different conditions [106, 108], between in vivo glycated HSA 
and in vitro glycated HSA that is prepared under non-physiolog-
ical conditions [119], or even between in vivo samples that are ac-
quired from different patients [93, 111]. Despite this variability, 
there are strong similarities between the results of structural stud-
ies that have been obtained for in vivo and in vitro glycated HSA. 
For instance, lysine 525 has consistently been found to be a major 
glycation site in both types of samples [76, 78, 108]. In addition, all 
lysines that have been found to be modified in five or more studies 
of glycated HSA have been detected both in vivo and in vitro (see 
Figure 5); glycation at many of the remaining lysines in HSA has 
been observed in these two types of samples as well. There is also 
good agreement between the types of AGEs that have been found 
for in vivo and in vitro glycated HSA (see Table 1) and in the argi-
nines that have been most often observed to take part in glycation-
related modifications in these samples (see Figure 5).
Several recent studies have further noted close similarities be-
tween in vivo results and those for in vitro glycated HSA that has 
been prepared using glucose/HSA concentrations and incubation 
conditions that mimic those found in serum during diabetes. These 
similarities include the specific residues that are being modified [76, 
78, 105–108, 110], the types of modifications that occur [105–107, 110], 
the relative order of modified lysines versus lysine 525 in terms of 
their formation of fructosyl–lysine [93, 108], and the observed mod-
ification patterns versus in vivo glycated HSA that has a similar ex-
tent of overall glycation [106, 108, 110]. Together, these data indicate 
that in vitro glycated HSA can be a useful model for in vivo glycated 
HSA in many situations, especially if the two types of samples have 
been created or generated under similar reaction conditions.
5. Kinetic and thermodynamic studies of albumin 
glycation
The rate of modification and thermodynamics of the glyca-
tion process for HSA have been examined in a few studies. For in-
stance, early work in this area confirmed the reaction model that 
Figure 5. Number of reports from the literature (see Table 1) that have identified glycation-related modifications at the various lysine or arginine 
residues in HSA. The three regions of the bar graphs show the number of reports that have involved in vitro samples (bottom section, dark gray; 
up to 8 total papers), in vivo samples (middle section, light gray; up to 5 total papers) or plasma that was spiked with glucose and incubated under 
in vitro conditions (top section, intermediate gray; up to 1 paper).
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is shown in Figure 1(a) for the early stage glycation of HSA [15]. 
This process involves biphasic kinetics, in which the reversible 
combination of glucose with a free amine group to create a Schiff 
base quickly reaches an equilibrium (i.e., in a matter of hours un-
der the conditions used in Ref. [15]), followed by a much slower 
conversion of the Schiff base to an Amadori product. The average 
rate constants for the initial association or dissociation of glucose 
with amine groups on HSA were determined to be 1.5 M− 1 h− 1 (or 
4.2 × 10− 4 M− 1 s− 1) and 0.39 h− 1 (or 1.1 × 10− 4 s− 1), respectively 
(Note: unless otherwise indicated, the rate constants and equilib-
rium constants listed in this review were obtained at pH 7.4 and 
37 °C). The average association equilibrium constant for this pro-
cess was 3.9 (± 0.3) M− 1. The rate constant for the formation of 
Amadori products was estimated to be 0.026 h− 1 (7.2 × 10− 6 s− 1), 
with these products being found to be quite stable and having a 
half-life of at least 3 weeks [15].
Figure 6. Structures of fructosyl–lysine (FL) and examples of advanced glycation end-products (AGEs) that have been reported for glycated HSA 
(see summary in Table 1).
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The net rate of glycation and modification for HSA has been in-
vestigated in a number of studies under in vitro conditions. The re-
sults of one such study are shown in Figure 7(a), as based on the 
measurement of fructosamine and the overall degree of glycation 
[106]. Similar trends have been noted when using the change in 
mass that is observed over time for in vitro glycated HSA [111]. The 
results in both Figure 7(a) and (b) were carried out under incuba-
tion conditions and using concentrations of glucose and HSA that 
are representative of physiological conditions. The data show that 
most modifications occur within the first three weeks of incubation, 
followed by a more gradual change over longer incubation times 
[106, 111]. Comparable trends have been noted in other reports exam-
ining the reaction of HSA or BSA with glucose or similar reagents 
[77, 80, 120–122]. Besides incubation time, the effects of glucose con-
centration and pH on glycation have also been considered [122].
The formation over time of early stage glycation products ver-
sus AGEs has been investigated as well. As an example, both semi-
quantitative and quantitative studies of in vitro glycated HSA that 
was prepared under physiological or diabetic-type conditions (i.e., 
a 24- to 48-fold mol excess of glucose versus 0.63 mM HSA) have 
found that early stage glycation products such as FL dominate af-
ter incubation times of two weeks, with AGEs becoming more ap-
parent after longer reaction times of up to five weeks [106, 108]. A 
similar trend has been noted in vitro when using a larger excess of 
glucose versus HSA during glycation (i.e., 3125-fold mol excess of 
glucose versus 16 μM HSA) [80].
In some cases, the rate of formation of glycation products at 
specific regions of HSA has been determined, as shown in Fig-
ure 7(b). It has been found through this research that different re-
gions of this protein do vary in their rates of glycation product for-
mation [108]. For instance, the pseudo-first order rate constants for 
the formation of glycation products at regions containing the N-
terminus, K525, K439/R428 and K199 (or K205) have been esti-
mated to be 2.5 × 10− 5, 2.2 × 10− 5, 1.1 × 10− 5 and 1.1 × 10− 5 min− 1, 
respectively, over the first two weeks of incubation, with values 
of 1.3 × 10− 5 min− 1 to 0.6 × 10− 5 min− 1 being obtained over five 
weeks of incubation. Similar modifications at other regions of gly-
cated HSA have been found to have pseudo-first order rate con-
stants in the range of 10− 6 to 10− 5 min− 1 [108].
6. Binding of glycated albumin to drugs, fatty acids and 
other solutes
Because glycation can modify the structure of HSA, there has 
been interest in how these changes may affect the ability of HSA 
to act as a binding agent for drugs and other solutes [70–75, 82, 110, 
119, 123–131]. This topic has been of particular interest in recent 
years as experiments examining the structure of glycated HSA 
have found that modifications in this protein can occur on several 
residues that are at or near Sudlow sites I and II, as illustrated in 
Figure 3 [99, 100, 105–108]. Various methods have been employed 
to examine the binding of solutes with glycated HSA to see if 
any changes occur versus the interactions that are seen for nor-
mal HSA. These techniques have included fluorescence spectros-
copy [71, 82, 83, 119], circular dichroism [83], ultrafiltration [119, 123, 
130], equilibrium dialysis or rate of dialysis [70, 82, 124, 131, 132], and 
chromatographic techniques such as the Hummel–Dreyer method 
[130] or various forms of high performance affinity chromatogra-
phy [72–75, 126–129].
Several reports have studied the effects that glycation may have 
on drug and solute binding at the major binding regions for these 
agents on HSA. For instance, warfarin and its enantiomers have 
been used as site-selective probes for Sudlow site I of HSA [71–75, 
83, 110, 126, 128, 133]. The changes that have been observed for bind-
ing by warfarin to HSA have been found to vary with the binding 
conditions and the extent of glycation for HSA. For instance, early 
reports using fluorescence spectroscopy or equilibrium dialysis at 
20–25 °C noted a 6.9-fold decrease or 1.8-fold increase in the affin-
ity for warfarin with in vitro glycated HSA that had high amounts 
of glycation (i.e., as prepared using up to a 165- to 3300-fold mol 
excess of glucose versus HSA) [70, 71, 74]. An affinity decrease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of ~ 20% for warfarin was observed using a pooled sample of in 
vivo glycated HSA isolated from diabetic patients; in the same 
study, a decrease in affinity of 30–60% was seen for in vitro gly-
cated HSA that had been prepared by incubating a pooled sample 
of normal HSA with a 67- to 270-fold mol excess of glucose [119]. 
Other experiments have examined the binding of warfarin with in 
vitro glycated HSA that had been prepared by using glycation lev-
els similar to those present in patients with diabetes, with no sig-
nificant change in the overall binding or interactions at Sudlow 
site I being observed when compared to normal HSA [74]. Little or 
no change in binding was also observed for warfarin at pH 7.0 and 
room temperature with in vitro glycated HSA that had moderate 
amounts of modification [83], and when using chromatographic-
based zonal elution studies to examine the overall binding of war-
farin with entrapped samples of normal HSA or in vitro glycated 
HSA with modification levels comparable to those seen in diabetic 
patients [126]. One practical consequence of these latter observa-
tions is that no appreciable effect of glycation would be expected 
in clinical and pharmaceutical studies that use warfarin as a site-
selective probe with HSA that has levels of modification similar to 
those seen in diabetes [74, 126].
Similar experiments have examined the binding of l-trypto-
phan as a site-selective probe for Sudlow site II of glycated HSA 
and normal HSA [72–75, 110, 126, 128, 134]. Early studies using HSA 
that was glycated in vitro in the presence of bound palmitic acid 
did not show any apparent change in the affinity of l-tryptophan 
versus normal HSA at 25 °C [132]. However, a later study found a 
decrease in binding at 4 °C and when using a low amount of in 
vitro glycation (i.e., 9-fold mol excess of glucose versus 0.6 mM 
HSA), while an increase in binding was seen at a higher glycation 
level (i.e., a 46-fold mol excess of glucose versus 0.6 mM HSA) 
[82]. This result is consistent with recent competition experiments 
carried out at 37 °C and using in vitro glycated HSA that contained 
Figure 7. Change in (a) the total amount of glycation or (b) the 
amount of modification at specific residues as a function of time for in 
vitro glycated HSA. The data in both plots were acquired at pH 7.4 and 
37° C for 0.63 mM HSA incubated with 15 mM glucose. In (b) the rel-
ative extent of modification is given by the value of the measured gly-
cated/control index, as obtained for residues 1–10 (○), 521–531 (□), 
189–208 (Δ), and 426–442 (◊) and containing potential modifica-
tion sites such as the N-terminus, R521/K525, K199/K205 and R428/
K439. Adapted with permission from Refs. [106, 108].
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an extent of modification similar to those found in diabetes; in this 
latter work, a 4.7- to 5.8-fold increase in the association equilib-
rium constant for l-tryptophan at Sudlow site II was measured for 
glycated HSA [74]. A similar, large increase in affinity was seen at 
37 °C with comparable HSA samples but using a high-throughput 
chromatographic method to examine the overall binding of l-tryp-
tophan with normal HSA and in vitro glycated HSA [126]. Thus, in 
the case of l-tryptophan, glycation would be expected to have an 
effect in clinical and pharmaceutical research that uses this solute 
as a site-selective probe with HSA [74, 126].
Another group of drugs that may have their binding to HSA af-
fected by glycation are sulfonylureas [72, 73, 75, 110, 126–129]. Sul-
fonylureas are a form of oral medication that is used in the treat-
ment of type 2 diabetes. These drugs are highly bound to HSA and 
have been found to have multi-site interactions at both Sudlow sites 
I and II [72, 73, 75, 110, 127, 128, 135]. Table 2 summarizes the results 
of studies have examined the binding of several sulfonylureas with 
glycated HSA that has been prepared in vitro and with various de-
grees of glycation similar to those found in diabetic patients [72, 73, 
75, 128]. As this table indicates, the amount of HSA glycation has 
been found to affect the affinity of this protein for these sulfonylurea 
drugs. The size of this effect can vary from one drug to the next in 
the same class or between different binding sites for the same drug, 
and can lead to either an increase or decrease in affinity at a given 
site. For instance, the changes in affinity seen at Sudlow sites I and 
II in Table 2 range from 0.6-fold to 6.0-fold versus normal HSA for 
the given set of sulfonylurea drugs. Similar effects and variations in 
affinity at comparable levels of glycation have been noted in recent 
studies examining the binding by many of the same sulfonylurea 
drugs with in vivo samples of glycated HSA [110].
As Table 2 indicates, there is growing evidence that the amount 
of glycation-related modifications can have a large effect on the 
binding of a drug or solute with glycated HSA. This has been noted 
not only for sulfonylurea drugs [72, 73, 75, 110, 128] but is also sug-
gested by the apparent changes in affinity with glycation condi-
tions that have been noted in the binding studies that were dis-
cussed earlier for warfarin [70, 71, 74, 119, 126] and l-tryptophan [74, 
82, 126, 132]. In some cases, such as for warfarin, a large change 
in the extent of glycation may be needed to see a change in bind-
ing, while for other solutes (e.g., l-tryptophan) these changes may 
begin at small or moderate amounts of modification. It has been 
further proposed through structural studies (see Section 4) that 
the variations in binding that have been noted at particular sites 
on HSA (e.g., Sudlow sites I and II) are probably related to that 
changes in the amount and types of modifications that occur in 
HSA with different degrees of glycation [72–75, 82, 83, 106, 108, 110].
The binding of other solutes with glycated HSA has also been 
examined [26, 70, 83, 119, 122–25, 130, 131]. For instance, it has been 
reported that the dye Bromocresol Purple has a decrease in bind-
ing with glycated HSA, especially when this protein is reacted with 
glyceraldehyde, and that this change in binding is linked to the de-
gree of modification [70]. A decrease in the binding capacity of sa-
licylate has been observed for in vitro glycated HSA [122]. It was 
found for in vitro glycated HSA with moderate amounts of glyca-
tion that there is a decrease in the binding of dansylproline, which 
binds to Sudlow site II, but no measurable change for dansyl-
amide, which binds to Sudlow site I; decreased binding was fur-
ther seen for phenybutazone, ibuprofen and flufenamic acid [83]. 
The binding of in vivo glycated HSA with hemin did not change, 
but a 50% decrease in affinity for bilirubin was observed [26]. A de-
crease in affinity of 30–50% was seen for ketoprofen in its binding 
to a pooled sample of in vivo glycated HSA from diabetic patients, 
while either no change or up to a 50% decrease was observed for in 
vitro glycated HSA that had been prepared by using a 67- to 270-
fold mol excess of glucose [119]. In some studies, no change was 
found in the free fraction of phenytoin in spiked serum samples 
obtained from diabetic patients or normal individuals [123, 124], 
while another report found a significant decrease in the binding of 
phenytoin and valproate in such samples but no change for digi-
toxin [131]. Other studies have observed slightly decreased binding 
by diazepam to serum proteins in such samples [124, 125].
In addition to elevated amounts of protein glycation, diabetic 
patients have been found to have higher concentrations of fatty ac-
ids in serum when compared to healthy individuals [136–138]. As 
an example, in one early study it was proposed that an increase in 
free fatty acid concentrations was correlated with an increase in 
the free fraction of valproic acid in spiked serum samples from di-
abetic patients versus normal individuals [123]. In another study, 
a 20-fold decrease in binding strength was reported for the fatty 
acid cis-parinaric acid when comparing in vivo and in vitro gly-
cated HSA with normal HSA [26]. Fatty acids can have many bind-
ing regions on HSA and often interact strongly with these sites [27, 
30, 139–143]. In addition, some fatty acids can have direct compe-
tition with drugs on HSA or lead to allosteric effects during the 
binding of drugs and other solutes with this protein [140, 141]. One 
recent study examined the combined effect of glycation and sev-
eral long chain fatty acids on the overall binding of HSA to a num-
ber of sulfonylurea drugs [144]. The results showed an increase in 
the global affinity of glycated HSA for the drugs that were exam-
ined, and a similar decrease in affinity to both normal HSA and 
glycated HSA for these drugs in the presence of many common 
long chain fatty acids [144].
A question that has often been raised in the investigation of 
drug and solute binding to glycated HSA is the possible clinical rel-
evance of these interactions. The answer will depend on the drug 
or solute that is being considered, the typical therapeutic or phys-
iological range of the drug/solute, the regions on HSA that are in-
volved in the interaction, and the degree of glycation for HSA. In 
some cases, this effect can be minimal, as has been observed for 
phenytoin or diazepam in spiked serum [123, 124] and warfarin in 
the presence of in vitro glycated HSA that has amounts of modifi-
Table 2. Changes in the binding of various sulfonylurea drugs at 
Sudlow sites I and II when comparing in vitro glycated HSA with 
normal HSA.
Relative change in association equilibrium constant (↑ or ↓)a
Drug and binding site gHSA1 gHSA2 gHSA3
Sudlow site I
Acetohexamide ↑ 1.4-fold N.S. (↓ 10%)b N.S. (< 5%)
Tolbutamide ↑ 1.3-fold ↑ 1.2-fold ↑ 1.2-fold
Gliclazide N.S. (< 10%) ↑ 1.9-fold N.S. (↑ 11%)b
Glibenclamidec N.S. (< 5%) ↑ 1.7-fold ↑ 1.9-fold
Sudlow site II
Acetohexamide ↓ 0.6-fold ↓ 0.8-fold N.S. (< 10%)
Tolbutamide ↑ 1.1-fold ↑ 1.4-fold ↑ 1.2-fold
Gliclazide ↓ 0.8-fold ↑ 1.3-fold ↓ 0.6-fold
Glibenclamidec ↑ 4.3-fold ↑ 6.0-fold ↑ 4.6-fold
a. This table is based on data obtained from Refs. [72, 73, 75, 128]. 
The results for each drug were obtained using the same prepa-
rations of in vitro glycated HSA and were measured at 37°C and 
in the presence of pH 7.4, 0.067 M potassium phosphate buf-
fer. The levels of glycation for the protein samples were as fol-
lows: gHSA1, 1.31 (± 0.05); gHSA2, 2.34 (± 0.13); and gHSA3, 
3.35 (± 0.14) mol hexose/mol HSA. The relative changes listed 
are all versus the following association equilibrium constants 
that have been measured for normal HSA: Sudlow site I — ace-
tohexamide = 4.2 × 104 M− 1, tolbutamide = 5.5 × 104 M− 1, glicla-
zide = 1.9 × 104 M− 1, glibenclamide = 2.4 × 104 M− 1; Sudlow site II 
— acetohexamide = 13.0 × 104 M− 1, tolbutamide = 5.3 × 104 M− 1, gli-
clazide = 6.0 × 104 M− 1, glibenclamide = 3.9 × 104 M− 1. The term 
“N.S.” stands for “not significant” and indicates an association equi-
librium constant that was not significantly different from that for 
normal HSA at the 95% confidence level.
b. The association equilibrium constant for this drug and sample of 
glycated HSA was significantly different at the 90% confidence level 
from the reference value for the same drug with normal HSA but was 
not significantly different at the 95% confidence level.
c. Glibenclamide also binds to the digitoxin site of HSA, which may 
have displayed a slight decrease in binding in going from normal 
HSA to the samples of in vitro glycated HSA that are represented in 
this table [128].
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cation similar to those seen in diabetes [73, 83, 126]. For other sol-
utes and drugs, there may be a large change in affinity or bind-
ing, as has been observed in serum, for in vivo glycated HSA, or 
for in vitro glycated HSA with glycation levels similar to those seen 
in diabetes. Examples of this latter case include l-tryptophan [74, 
126], cis-parinaric acid [26], bilirubin [26], and ketoprofen [119]. Al-
though further data is needed on these effects for a broader range 
of drugs, the results that have already been obtained suggest that 
Sudlow site II may be more prone to Sudlow site I to such changes. 
This generalization is illustrated by studies that have compared 
the binding of glycated HSA to drugs and probes that are known to 
bind to these two sites [72–75, 83, 110, 126, 127].
Even drugs with moderate changes in affinity might be affected 
to a significant degree if they have a relatively narrow therapeu-
tic range and/or undesirable effects at concentrations flanking this 
range. For instance, the sulfonylurea results in Table 2 for in vitro 
glycated HSA and similar data for in vivo glycated HSA [110] predict 
that the free, biologically-active fractions of these drugs could differ 
by 0.6- to 1.7-fold from what would be expected in serum at typical 
therapeutic concentrations and in the presence of only normal HSA. 
This difference is of concern for these drugs because a lower-than-
expected free fraction would lead to improper control of blood glu-
cose, while a higher-than-expected free fraction might lead to hypo-
glycemia [72, 75, 128, 129, 135, 145]. In addition to these direct changes 
in the free drug fractions, another way glycation may affect the be-
havior of such solutes is through the changes in drug–drug interac-
tions that might occur as the affinities of one or both drugs are al-
tered at Sudlow sites I and II or other regions of HSA [74, 128].
7. Conclusions
The glycation of HSA has been a topic of interest for several 
decades and especially over the last ten years. Part of this inter-
est is related to the clinical use of glycated HSA as a biomarker for 
the control of blood glucose over short-to-intermediate periods of 
time. To meet this need, a number of methods are now available to 
clinical laboratories for either the direct or indirect measurement 
of glycated HSA. With such methods, glycated HSA can be used as 
a complementary biomarker to blood glucose and Hb1Ac for mon-
itoring glycemic control in diabetic patients.
There has also been increasing interest in the effects glycation 
may have on the structure of HSA. A variety of methods have been 
employed for examining the number, location and types of modi-
fications that can occur in glycated HSA. Many possible modifica-
tion sites have been detected on this protein for both early stage 
glycation products and AGEs, but a smaller subset of these sites 
appear to take part in most of these reactions. Some information 
on the similarities, or differences, between in vivo and in vitro gly-
cated HSA has been acquired through such work. The overall rate 
of glycation, the thermodynamics of this process, and the rate of 
modification at specific regions have been considered in such stud-
ies. The role of glycation conditions on the types of modifications 
that are formed has also been examined.
Related work has appeared on the possible effects glycation 
may have on the properties of HSA, such as its ability to bind to 
drugs and other small solutes. This research has again employed 
various methods and has examined a growing list of solutes. This 
work has included compounds that are known to bind to HSA at 
specific regions (e.g., Sudlow sites I and II) and solutes with more 
complex binding, such as drugs that have multi-site binding to 
HSA (e.g., sulfonylurea drugs and fatty acids). The results have 
shown that the effects of glycation on binding by HSA can vary 
from one solute to the next, even within the same group of com-
pounds, and can vary for the same solute at different sites on HSA. 
These effects can be clinically significant and appear to vary with 
the extent of glycation and the glycation conditions.
Given the importance of HSA and the relatively complex na-
ture of glycation, it is anticipated that more research will be con-
ducted in the future to obtain further information on this process 
and on how it affects HSA. This information could lead to the de-
velopment of more effective assays for measuring glycated HSA 
as a biomarker for diabetes control. Such data would also be ex-
pected to create a better understanding of how diabetes and gly-
cation can alter the structure and function of proteins like HSA. 
This improved understanding could, in turn, result in new tools 
for studying the biochemical effects of diabetes and in the develop-
ment of better treatment regimes for diabetic patients.
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